GenSight Biologics
105 articles about GenSight Biologics
-
Here's a roundup of some of the top clinical trial news from the previous week.
-
BioSpace Global Roundup, May 16
5/16/2019
Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more. -
The 96-Week data showed continued efficacy of GS010 two years after injection, with best-corrected visual acuity (BCVA) holding a clinically meaningful improvement over baseline.
-
GenSight Biologics Reports Positive 96-Week Data from REVERSE Phase III Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON)
5/15/2019
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported a first set of results from Week 96 of the REVERSE Phase III clinical trial.
-
GenSight Biologics Announces Positive Data Safety Monitoring Board Review and Continuation of PIONEER Phase I/II Clinical Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa
5/7/2019
GenSight Biologics announced that the independent Data Safety Monitoring Board (DSMB) completed its first safety review of the ongoing PIONEER Phase I/II clinical trial of GS030 combining gene therapy and optogenetics for the treatment of Retinitis Pigmentosa.
-
GenSight Biologics Announces Presentation of 72-Week Data from the REVERSE Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)
5/6/2019
GenSight Biologics announced that the 72-week results from the REVERSE Phase III clinical trial of GS010 will be presented at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, Pennsylvania, United States, May 4-10, 2019.
-
GenSight Biologics Announces Presentation of 72-Week Data from the REVERSE & RESCUE Phase III Trials of GS010 at the Annual Meeting of ARVO
4/25/2019
GenSight Biologics announced that the 72-week results from the REVERSE and RESCUE Phase III clinical trials of GS010 will be presented at the 2019 Association for Research in Vision and Ophthalmology Annual Meeting in Vancouver, Canada, from April 28 to May 2, 2019.
-
Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.
-
GenSight Biologics Reports Positive Follow-up Results at Week 72 of the RESCUE Phase III Clinical Trial of GS010 in Leber Hereditary Optic Neuropathy (LHON)
4/17/2019
GS010-treated eyes showed continuous recovery of visual functions from nadir (worst vision post-treatment) in both best-corrected visual acuity (BCVA) and contrast sensitivity (CS)
-
GenSight Biologics Announces Presentation of 72-Week Data From the REVERSE Phase III Trial of GS010 at the 45th Annual Meeting of NANOS
3/15/2019
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today that the 72-week results from the REVERSE Phase III clinical trial of GS010 will be presented at the 45th Annual Meeting of the North American Neuro-Ophthalmology Society
-
GenSight Biologics Announces Publication of Positive Safety Data from Phase I/II Trial of GS010 in the JAMA Ophthalmology
2/12/2019
Intravitreal administration of GS010 in patients with LHON was safe and well tolerated
-
GenSight Biologics reports topline results at Week 48 of the RESCUE Phase III clinical trial of GS010 in subjects within six months of visual loss onset due to Leber Hereditary Optic Neuropathy (LHON)
2/4/2019
Mean best-corrected visual acuity (BCVA) among GS010-treated eyes and sham-treated eyes evolved with similar trajectories, worsening to a low point, or nadir, before beginning to improve by Week 48 – coherent with REVERSE trial
-
Shares of Paris-based GenSight plunged nearly 19 percent Monday after the company announced that its gene therapy for Leber hereditary optic neuropathy (LHON) failed to show a significant effect in patients at 48 weeks.
-
GenSight Biologics Reports Sustained Quality of Life Improvements at Week 72 of Phase III REVERSE Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON)
12/12/2018
Composite score and relevant sub-scores in the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) showed sustained improvements at Week 48 and Week 72
-
GenSight Biologics Enrolls First Subject in First-in-man PIONEER Phase I/II Clinical Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa
10/26/2018
GenSight Biologics today announced that the first subject was treated in the first-in-man PIONEER Phase I/II clinical trial of GS030 at the Moorfields Eye Hospital in London, United Kingdom.
-
GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)
10/18/2018
Clinically meaningful improvement of +15 ETDRS letters in visual acuity of treated eyes at Week 72
-
GenSight Biologics Provides an Update on the Clinical and Regulatory Pathways for GS010
9/13/2018
Additional Week 72 (18-month) data point for REVERSE expected in early Q4 2018
-
GenSight Biologics : Key Opinion Leaders Highlight GS010 Efficacy and Patient Benefits in Discussion of Findings from REVERSE Phase III Clinical Trial
6/20/2018
Preservation of anatomic structures combined with visual function improvement (contrast sensitivity) demonstrate neuro-protection in human genetic disease
-
Tilak Announces CE Marking for Odysight, Its First Mobile Medical Game in Ophthalmology
6/14/2018
Tilak announced that Odysight, its first mobile medical game dedicated to the monitoring of patients with chronic eye diseases, has achieved CE marking.
-
GenSight Biologics Reports Positive Additional Data from REVERSE Phase III Clinical Trial of GS010 for Treatment of Leber Hereditary Optic Neuropathy (LHON)
6/12/2018
GenSight Biologics today reported additional results from the REVERSE Phase III clinical trial.